卡培他滨对难治转移性乳腺癌的疗效与安全性的评价

目的研究卡培他滨在蒽环和紫杉类化疗失败的晚期乳腺癌的疗效和安全性,及其与激素受体和Her2状态与疗效关系。方法 61例晚期乳腺癌病人接受卡培他滨治疗,直到出现肿瘤进展或不能耐受毒性,分析其疗效及毒副反应。结果 CR、PR、SD和PD分别是1.7%、29.5%、39.3%和29.5%;ORR31.2%,临床获益率70.5%;平均缓解持续时间7.3个月,TTP6.0个月。ORR、临床获益率与TTP不受激素受体、Her2状态影响。大部分治疗相关性毒副反应是轻中度,可耐受。结论卡培他滨可能成为难治性转移性乳腺癌的治疗首选药物。

Analysis of Efficacy and Safety of Capecitabine on Refractory Metastatic Breast Cancer

Objective To analyze the efficacy and safety of capecitabine in metastastic breast cancer previously received anthracycline and taxanes.Methods 61 patients received capecitabine monothrapy,until the tumor progression.or appearing intolerant toxicity.Results CR,PR,SD and PD were 1.7%,29.5%,39.3% and 29.5%,respectively;ORRis 31.2%,clinical benefits 70.5%;mean duration of response 7.3 months,TTP 6.0 months.ORR,TTP and duration of response were not affected by the status of hormone receptor and Her2.However,the clinical benefit was affected by the status of hormone receptor.The majority of treatment-related adverse reactions were light and moderate,which was well tolerable.Conclusion Capecitabine may be the choice of treatment in refractory metastatic breast cancer.